Postmarketing Safety Gets Closer Focus In Latest US FDA Drugs Center Reorganization

 
• By Sue Sutter

Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.

Office move
Some US FDA drug safety and generic drug staff will move around under a new reorganization. • Source: Shutterstock

More from Drug Safety

More from Pink Sheet